



(51) International Patent Classification:

A61K 9/00 (2006.01)

A61K 9/19 (2006.01)

A61K 9/08 (2006.01)

A61K 9/127 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2020/059308

(22) International Filing Date:

01 April 2020 (01.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2019/058635

05 April 2019 (05.04.2019)

EP

(71) Applicant: BIONTECH RNA PHARMACEUTICALS

GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: HAAS, Heinrich; c/o BioNTech SE, An der

Goldgrube 12, 55131 Mainz (DE). HÖRNER, Sebastian;

c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).

HILLER, Thomas Michael; c/o BioNTech SE, An der

Goldgrube 12, 55131 Mainz (DE).

(74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwälte PartG

mbB, Hansastr. 32, 80686 Munich (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY

(57) Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.

